SMS Pharmaceuticals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+13.3%+19.3%
EBITDA+23.2%+46.5%
Net Income+47.6%—
EPS (adj.)+48.8%—
Total Assets+18.2%+15.7%
Total Equity+22.9%+19.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SMSPHARMA₹475.45

SMS Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABSOLARADCALUNICHEMLABGUFICBIORPGLIFEHIKALGUJTHEMMcap ₹4,453 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+13.3+19.3
EBITDA+23.2+46.5
Net Income+47.6—
EPS (adj.)+48.8—
Total Assets+18.2+15.7
Total Equity+22.9+19.5
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.